UNSPSC 51313111: Cetirizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64O047KTOA, chemically known as acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride, (+-)- but more generally known as cetirizine dihydrochloride, which bears US NIH Compound Identifier 55182.

European Medicines Agency schedules Cetirizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11803MIG. Most nations, for tariff and trade purposes, schedule cetirizine dihydrochloride under HS 29335995. SMILES: C1CCC(CC1)C(C2CCC(CC2)CL)N3CCN(CC3)CCOCC(=O)O.CL.CL.

UNSPSC 51313111 Cetirizine dihydrochloride, a Commodity code, nominally covers a single antihistamine product, but recent state and local solicitations tagged under this code actually procure naloxone, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products — indicating substantial misalignment between the code's narrow product name and the work being solicited. State and local governments buying under this code are sourcing emergency medications, pharmacy benefit program infrastructure, and bulk generic pharmaceutical inventories through county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The issuing bodies span county-level community health programs, state pharmacy benefit administration, and regional cooperative procurement vehicles serving multiple jurisdictions.

Recent activity centers in Florida and Minnesota, with broader multi-state reach through cooperative vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a two-year term plus one-year renewal option; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in multiple states including Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent of evaluation weight), manufacturing compliance with cGMP and DSCSA, and relationships with authorized wholesalers, while the Seminole County naloxone procurement requires E-Verify compliance and carries potential FEMA funding with associated federal environmental compliance obligations.